

Highly Potent and Efficient PROTAC-induced Brd4 Degradation

Drug Name	***0135
Description	A von Hippel-landau (VHL) E3 ligase-based proteolysis-targeting chimera consists of a potent Brd4 inhibitor conjugated to an antibody targeting c-type lectin domain family 12 member A (CLEC12) through a novel linker. The product showed significant antitumor activities without severe toxicity in preclinical studies.
Target	Brd4; CLEC12
Drug Modality	PROTAC
Indication	Leukemia
Product Category	Signal Transduction Modulators
Mechanism of Action	Targeting CLEC12 expressed on tumor cells to induce Brd4 degradation
Status	Preclinical
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.